Advice
following a resubmission:
infliximab (Remicade®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
In two randomised controlled studies, infliximab 5mg/kg intravenous infusion on weeks 0, 2 and 6 was significantly superior to placebo for the endpoint of clinical response at week eight.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice189KB (PDF)
Medicine details
- Medicine name:
- infliximab (Remicade)
- SMC ID:
- 374/07
- Indication:
- treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
- Pharmaceutical company
- MSD
- BNF chapter
- Gastro-intestinal system
- Submission type
- Resubmission
- Status
- Superseded
- Date advice published
- 12 May 2014